StocksMedium•4 November 2026•
1 min read
Maravai LifeSciences Beats Q3 2026 Revenue and Earnings Estimates
Key Facts
1Maravai LifeSciences reported third-quarter 2026 financial results that exceeded analyst expectations for both revenue and earnings per share.
Maravai LifeSciences reported third-quarter 2026 financial results that exceeded analyst expectations for both revenue and earnings per share. Benzinga reported that the company's performance delivered a beat on both top and bottom-line estimates for the period.
MRVI closed at $7.45 on November 3, 2026, with the stock reaching a day high of $7.76 and a low of $7.33 during that session. The stronger-than-projected financial performance supports positive sentiment for the life sciences and biotechnology firm.